Cardiotonic capsule for treating chronic heart failure

Abstract

The invention discloses a cardiotonic capsule for treating chronic heart failure and belongs to the field of traditional Chinese medicines. A preparation method of the cardiotonic capsule comprises the following steps of mixing 3-5 parts by mass of milkvetch root, 3-5 parts by mass of red ginseng, 3-5 parts by mass of prepared monkshood, 2-10 parts by mass of semen lepidii, 3-5 parts by mass of radix ophiopogonis, 2-3 parts by mass of Chinese magnoliavine fruit, 2-3 parts by mass of polygonatum odoratum, 3-5 parts by mass of radix salviae miltiorrhizae, 2-3 parts by mass of ligusticum wallichii, 3-5 parts by mass of kudzuvine root powder, 3-5 parts by mass of radix notoginseng and 3-5 parts by mass of leech, crushing the mixture into fine powder, and filling the fine powder into capsules. The cardiotonic capsule for treating chronic heart failure does not produce any toxic and side effect, is not limited by contraindication, has good effects of treating chronic constrictive and diastolic heart failure, is especially suitable for diastolic heart failure, can improve heart failure symptoms, can correct heart failure pathological and physiological changes, can reverse atherosclerosis, and can improve ischemic myocardial injuries, cardiac muscle and blood vessel remodeling and long-term prognosis of heart failure patients.

Description

technical field [0001] The invention relates to a traditional Chinese medicine, in particular to a strong heart capsule for treating chronic heart failure. Mainly used in the treatment of chronic heart failure. Background technique [0002] The most common cause of chronic heart failure is ischemic myocardial damage, and the most common cause of ischemic myocardial damage is hypertension and coronary heart disease. At present, hypertension and coronary heart disease are the first killers that affect human health. Hypertension and coronary heart disease often cause chronic diastolic heart failure. Finding a treatment for diastolic heart failure can not only have positive inotropic effects, but also improve the prognosis of chronic heart failure. Insufficient myocardial blood and energy supply and drugs to improve ischemic myocardial damage are urgent problems to be solved in the medical field. [0003] The myocardium of patients with chronic heart failure is in a state of i...

AI Technical Summary

Problems solved by technology

[0003] The myocardium of patients with chronic heart failure is in a state of insufficient blood and energy supply. Excessive long-term use of cardiac glycosides will expand the contradiction between supply and demand of myocardial energy, making myocardial damage more serious, and leading to increased mortality.

Cardiotonic drugs commonly used clinically have a history of more than 200 years, and the fact that they can improve the symptoms of heart failure is recognized. However, large-scale studies have proved that its long-term effect cannot reduce the total mortality rate from heart failure. In terms of overall treatment, relying solely on inotropic drugs, only focusing on temporary symptom improvement, cannot correct the pathophysiological changes of heart failure, and cannot improve the long-term prognosis, and cardiac glycosides have many contraindications and severe Toxic and side effects limit the clinical application, only suitable for chronic systolic heart failure, and contraindicated for chronic diastolic heart failure